Monoclonal antibody 266

Drug Profile

Monoclonal antibody 266

Alternative Names: Anti-Abeta Antibody m266 Fab; Anti-beta-amyloid monoclonal antibody 266; Biotinylated m266 antibody - Eli Lilly; m266; m266 Fab; m266B antibody - Eli Lilly

Latest Information Update: 24 Jul 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Washington University School of Medicine
  • Developer Eli Lilly
  • Class Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 24 Jul 2006 Data presented at the 10th International Conference on Alzheimer's Disease and Related Disorders (ICAD-2006) have been added to the pharmacokinetics and Alzheimer's Disease and Cognition Disorders pharmacodynamics sections
  • 21 Jul 2006 Discontinued - Preclinical for Alzheimer's disease in USA (Injection)
  • 21 Sep 2001 Preclinical development for Alzheimer's disease in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top